Cytek Biosciences, Inc. filed its quarterly report on Form 10-Q with the SEC on November 4, 2026, covering the fiscal quarter and nine-month period ended September 30, 2026.

Key Highlights

  • Total revenue: Net revenue for the nine months ended September 30, 2026 was $145.504 million, compared with $139.352 million for the same period in 2025, according to the filing.
  • Third-quarter revenue: Total net revenue for the three months ended September 30, 2026 was $53.229 million, up from $52.293 million in the prior-year quarter.
  • Net loss: The company reported a net loss of $6.097 million for the third quarter of 2026 and $37.121 million for the nine months ended September 30, 2026.
  • Gross profit: Gross profit for the nine-month period was $80.800 million, compared with $71.575 million for the nine months ended September 30, 2025.
  • Total assets: As of September 30, 2026, total assets were $446.145 million, down from $461.542 million at December 31, 2025.
  • Shares outstanding: 130,771,456 shares of common stock were issued and outstanding as of September 30, 2026, per the balance sheet.
  • Accumulated deficit: The accumulated deficit stood at $138.858 million as of September 30, 2026, compared with $101.738 million at December 31, 2025.

Cytek Biosciences Financial Results for the Quarter and Nine Months Ended September 30, 2026

Cytek Biosciences, Inc. (NASDAQ:CTKB), a life sciences instrument and reagent company headquartered in Fremont, California, reported its unaudited consolidated financial results for the period ended September 30, 2026. The filing shows total net revenue of $53.229 million for the third quarter of 2026, comprised of $37.161 million in product revenue and $16.068 million in service revenue. For the nine-month period, product revenue was $98.496 million and service revenue was $47.008 million, bringing the nine-month total to $145.504 million.

Operating expenses for the nine months ended September 30, 2026 totaled $119.086 million, including research and development costs of $28.700 million, sales and marketing expenses of $36.731 million, and general and administrative expenses of $53.655 million. The resulting loss from operations for the nine-month period was $38.286 million, according to the filing. Net loss per share, basic and diluted, was $0.05 for the third quarter and $0.29 for the nine months ended September 30, 2026.

On the balance sheet, the company reported cash and cash equivalents of $66.806 million and marketable securities of $89.093 million as of September 30, 2026, alongside total stockholders' equity of $321.354 million. Total liabilities were $124.791 million, including deferred revenue of $30.281 million (current) and $18.744 million (noncurrent). The company carried $16.691 million in goodwill and $14.028 million in net intangible assets on its balance sheet at the period end.

What Was Disclosed

Cytek Biosciences disclosed its unaudited consolidated financial statements for the quarter and nine months ended September 30, 2026, including revenue, operating expenses, net loss, balance sheet data, and changes in stockholders' equity, as part of its quarterly Form 10-Q filing dated November 4, 2026.